Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C26H34F5NO4 |
Molecular Weight | 519.5445 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC=C([C@H](C)OCC(=O)NCC(F)(F)C(F)(F)F)[C@@]1(C)CCC\C2=C/C=C3/C[C@@H](O)C[C@H](O)C3=C
InChI
InChIKey=SVCSMAZYWOQCBW-NVJMFHFGSA-N
InChI=1S/C26H34F5NO4/c1-15-18(11-19(33)12-22(15)34)7-6-17-5-4-10-24(3)20(8-9-21(17)24)16(2)36-13-23(35)32-14-25(27,28)26(29,30)31/h6-8,16,19,21-22,33-34H,1,4-5,9-14H2,2-3H3,(H,32,35)/b17-6+,18-7-/t16-,19+,21-,22-,24+/m0/s1
Pefcalcitol (previously known as M518101), an analog of vitamin D3 (VD3), is an antipsoriatic drug candidate that is designed to achieve much higher pharmacological effects, such as keratinocyte differentiation. This drug is a phosphodiesterase inhibitor and is being developed as a topical ointment formulation. Pefcalcitol was involved in phase III clinical trials in the USA and in Japan in subjects with plaque psoriasis and with palmoplantar keratoderma. In addition, it participated in phase II clinical trial for the warts treatment.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01908595
Psoriasis: proper quantity twice daily
Route of Administration:
Topical
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB11786
Created by
admin on Sat Dec 16 04:18:37 GMT 2023 , Edited by admin on Sat Dec 16 04:18:37 GMT 2023
|
PRIMARY | |||
|
AB-141
Created by
admin on Sat Dec 16 04:18:37 GMT 2023 , Edited by admin on Sat Dec 16 04:18:37 GMT 2023
|
PRIMARY | |||
|
381212-03-9
Created by
admin on Sat Dec 16 04:18:37 GMT 2023 , Edited by admin on Sat Dec 16 04:18:37 GMT 2023
|
PRIMARY | |||
|
16122802
Created by
admin on Sat Dec 16 04:18:37 GMT 2023 , Edited by admin on Sat Dec 16 04:18:37 GMT 2023
|
PRIMARY | |||
|
C170289
Created by
admin on Sat Dec 16 04:18:37 GMT 2023 , Edited by admin on Sat Dec 16 04:18:37 GMT 2023
|
PRIMARY | |||
|
CHEMBL3137307
Created by
admin on Sat Dec 16 04:18:37 GMT 2023 , Edited by admin on Sat Dec 16 04:18:37 GMT 2023
|
PRIMARY | |||
|
100000175515
Created by
admin on Sat Dec 16 04:18:37 GMT 2023 , Edited by admin on Sat Dec 16 04:18:37 GMT 2023
|
PRIMARY | |||
|
9573
Created by
admin on Sat Dec 16 04:18:37 GMT 2023 , Edited by admin on Sat Dec 16 04:18:37 GMT 2023
|
PRIMARY | |||
|
KT5224XSHW
Created by
admin on Sat Dec 16 04:18:37 GMT 2023 , Edited by admin on Sat Dec 16 04:18:37 GMT 2023
|
PRIMARY | |||
|
DTXSID70109851
Created by
admin on Sat Dec 16 04:18:37 GMT 2023 , Edited by admin on Sat Dec 16 04:18:37 GMT 2023
|
PRIMARY |
ACTIVE MOIETY